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Abstract: (1) Introduction: The incidence of venous thromboembolisms (VTE) has not been extensively
analyzed in patients with antineutrophil cytoplasmic antibody (ANCA)-glomerulonephritis
(ANCA-GN). Thus, the aim of the present study was to assess the frequency and the risk factors of
VTE in patients with ANCA-GN. (2) Methods: Patients from the Maine-Anjou ANCA-associated
vasculitis (AAV) registry with a biopsy showing pauci-immune glomerulonephritis were included.
VTE events, site, and interval from AAV diagnosis were analyzed. (3) Results: 133 patients fulfilled
the inclusion criteria of the study and were analyzed. VTE episodes were diagnosed in 23/133
(17.3%) patients at a median delay of 3 months from ANCA-GN diagnosis. Patients with VTE had
lower serum albumin (p = 0.040), were less frequently on statin therapy (p = 0.009) and had less
frequently proteinase-3 (PR3)-ANCAs (p = 0.078). Univariate analysis identified higher age (p = 0.022),
lower serum albumin (p = 0.030), lack of statin therapy (p = 0.009), and rituximab treatment (p = 0.018)
as significant risk factors of VTE. In multivariate analysis, only lack of statin therapy (HR 4.873;
p = 0.042) was significantly associated with VTE. (4) Conclusion: Patients with ANCA-GN are at high
risk of VTE, especially within the first months following AAV diagnosis. Our results suggest that
statin therapy is associated with a lower risk of VTE in ANCA-GN patients.
Keywords: venous thromboembolism; ANCA glomerulonephritis; statins; risk factor
1. Introduction
Venous thromboembolism (VTE) is a classical complication of chronic inflammatory diseases [1],
reported to be increased in many auto-immune and rheumatic diseases, including ANCA-associated
vasculitis (AAV) [2–9]. The first studies specifically addressed in AAV were a case series of pediatric
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patients that developed deep vein thrombosis (DVT) shortly after disease diagnosis [10] and a post-hoc
analysis of the Wegener’s Granulomatosis Etanercept Trial (WGET) [2,11]. In this prospective trial,
which was limited to patients with granulomatosis with polyangiitis (GPA), about 10% of patients
developed VTE after a median time of 2.1 months from disease onset [11]. The increased risk of
VTE in AAV patients was confirmed in further retrospective studies [4,5]. Stassen et al. reported an
incidence of 12% of VTE in a cohort of 193 patients with micropolyangitis (MPA) or GPA, followed for
6.1 years [4]. A similar incidence was observed in a recent analysis performed in 417 patients that
were included in randomized controlled trials conducted by the European Vasculitis Society [5].
In this analysis, patients with severe renal disease had a higher rate of VTE. In the multivariate
analysis, increased C-reactive protein level and increased creatinine cutaneous and gastrointestinal
involvement at diagnosis were independently associated with VTE. However, the analysis of VTE
risk factors was limited given the heterogeneity of patients pooled from four different studies, and by
unavailability of detailed data at disease onset. Kronbichler et al. analyzed VTE frequency and risk
factors in patients included in the RAVE study which aimed at evaluating rituximab as a remission
induction regimen [9,12]. In these patients without severe kidney involvement, pulmonary hemorrhage,
and positive PR3-ANCA, heart involvement and microscopic hematuria were found to be independently
associated with VTE development. More recently, Isaacs et al. found PR3-ANCA, hypoalbuminemia,
and BMI to be independent risk factors of VTE in a retrospective analysis in 162 AAV patients [13].
Kidney involvement in AAV appears as a major prognostic factor [14] and impaired kidney
function has been reported as a risk factor of VTE [5]. Finally, no study has specifically addressed VTE
risk factors in ANCA-glomerulonephritis (ANCA-GN) patients and whether factors identified in past
studies apply to ANCA-GN patients. Moreover, whether ANCA-GN patients experiencing VTE have
a different prognosis remains to be studied.
The AAV Maine-Anjou registry includes all patients diagnosed with ANCA-GN from the Maine
Anjou Region in France, encompassing one university and three regional hospitals [15]. The registry
gathers very detailed clinical and biological data of patients with ANCA-GN since 2000, as well as
treatment management and outcomes.
Thus, in the present study, we used the AAV Maine-Anjou registry to study VTE episodes in
patients with biopsy confirmed ANCA-GN. The primary objective was to analyze the incidence of
VTE in ANCA-GN patients and the secondary objectives were to identify risk factors of VTE and to
study the outcome of patients according to VTE occurrence.
2. Material and Methods
2.1. Maine-Anjou Registry
The Maine-Anjou registry is a retrospective-prospective registry which was created on 1 January
2018. The database includes adult patients with ANCA-GN diagnosed since 1 January 2000 in
Nephrology departments of 4 hospitals (Angers University Hospital and Regional Hospital of Le Mans,
Cholet and Laval). Patients are included in the registry if aged over 18-years-old, if they fulfill Chapel
Hill Consensus Conference criteria for AAV [16], and have presumed or confirmed renal involvement
of vasculitis. Data concerning characteristics, presentation (clinical and biological data), treatment,
and outcomes are collected in the registry. Data were collected retrospectively before 1 January 2018
and prospectively after 1 January 2018. On the 1 January 2019, the registry had data from 165 patients.
The registry has been declared and has been authorized by the “Commission National Informatique
et Liberté” (CNIL, agreement number 2018-MR03-02). In accordance with French law, participants gave
their non-opposition to be included in the registry and for the use of their data in an anonymous form.
2.2. Inclusion Criteria in the Study and Data Collection
Patients from the registry were eligible for inclusion in the study if they had pauci-immune
glomerulonephritis confirmed at kidney biopsy and a follow-up of at least 6 months. Patients were
J. Clin. Med. 2020, 9, 3177 3 of 11
followed from ANCA-GN diagnosis until end of follow-up or death. Relapsing patients had ANCA-GN
at relapse and were followed from relapse to the end of follow-up. VTE, their sites, and their timing
according to ANCA-GN onset were collected, as well as risk factors of VTE, antiplatelet or/and
anti-thrombotic ongoing treatments at ANCA-GN diagnosis. Thrombotic episodes of the arterio-venous
fistulae for hemodialysis were excluded.
Data were retrieved from the registry: Age, gender, weight, height, and comorbidities; the nature
and type of injuries of the affected organs at AAV presentation were listed. The AAV activity was
determined using the Birmingham Vasculitis Activity Score (BVAS) 2003 [17]. Biological parameters at
diagnosis were also retrieved, as well as medications at AAV diagnosis. The glomerular filtration rate
was calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) study equation [18].
Kidney biopsy results were also retrieved when available. All kidney biopsies from the four
centers are analyzed centrally in the department of Pathology of the University Hospital of Angers by
two nephropathologists. Only biopsies showing more than 7 glomeruli were considered in the present
study. The analysis of kidney biopsies is routinely reported in a standardized pathological report
allowing classification according to the Berden histopathological classification of ANCA-GN [14].
The study protocol complied with the Ethics Committee of the Angers University Hospital
(n 2020/84).
2.3. Treatments and Definitions
The therapeutic regimens used to induce and maintain AAV remission was left at the clinician
discretion. AAV subtype (GPA and MPA) was classified according to the European Medicines Agency
(EMA) vasculitis classification algorithm [19]. Renal disease characterization was based on kidney
biopsy and clinical data (active urinary sediment, proteinuria, and impaired renal function). Renal death
was defined as the need for renal replacement therapy (RRT) for more than 3 months. VTE episodes
were considered if confirmed by ultrasounds or CT scan. The prognosis associated with the occurrence
of VTE following the first 3 months since ANCA-GN diagnosis (early VTE) was also evaluated.
2.4. Statistical Analysis
Continuous variables are presented as the mean ±SD or median and interquartile range
(IQR) when applicable. Categorical variables are presented as the absolute value and percentage.
Differences between groups were analyzed using the χ2 test (or Fisher exact test when applicable)
for categorical variables and the Mann–Whitney U test for continuous variables. The Kaplan–Meyer
method was used to analyze VTE-free survival. Cox proportional hazards regression analysis was
performed to examine factors associated with VTE and are reported as hazard ratio (HR) with 95% CIs.
Multivariate Cox regression analysis included all parameters that were correlated with VTE occurrence
in the univariate analysis (p < 0.05). All the statistical tests were performed to the two-sided 0.05 level
of significance. Statistical analysis was performed using SPSS software® 23.0 (IBM, Armonk, NY, USA)
for Mackintosh and Graphpad Prism® 7 (San Diego, CA, USA).
3. Results
3.1. Characteristics of the Population
Among 165 patients included in the Maine-Anjou AAV registry, 145 underwent a kidney biopsy at
AAV onset or at relapse. Among these 145 patients, 141 had a kidney biopsy showing pauci-immune
glomerulonephritis. Eight patients were excluded because of missing data and/or unavailable follow-up.
Thus, 133 patients were included in the present study (Figure 1). The mean age at presentation was
65.1± 14.1 years with a predominance of males (63.2%), 45 patients had GPA and 88 MPA. MPO-ANCAs
were detected in 86 (64.7%) patients and PR3-ANCAs in 39 (29.3%) patients. Eight patients were
MPO/PR3 ANCA negatives.
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BVAS was 17.2± 6.1 at disease onset or relapse. Median serum creatinine and eGFR at presentation
were 279.0 µmol/L and 20.7 mL/min/1.73 m2, respectively.
Cyclophosphamide was predominantly us d as remission induction treatment, all patients
received steroids nd 38 (28.6%) were trea ed with plasma exchange. The medi n follow-u of the
cohort was 40.5 mo ths.
During follow-up, 35 (26.3%) patients developed end-stage renal disease (ESRD) and 26 (19.5%)
died. Baseline characteristics of patients at the time of kidney biopsy are presented in Table 1.
Table 1. Baseline characteristics of the population and outcome.
All, n = 133
Baseline characteristics
Gender, M/F 84/49
Age, years 65.1 ± 14.1
BMI, kg/m2 24.6 ± 4.5
BMI > 30 kg/m2, n (%) 14 (10.5)
Heart disease, n (%) 15 (11.3)
Atrial fibrillation, n (%) 7 (5.3)
Past history of cancer, n (%) 19 (14.3)
ANCA-associated vasculitis characteristics
Clinical diagnosis, n (%)
Newly diagnosed 122 (91.7)
GPA/MPA 45 (33.8)/88 (66.2)
ANCA subtype, n (%)
PR3 ANCA 39 (29.3)
MPO ANCA 86 (64.7)
ANCA negative 8 (6.0)
BVAS at kidney biopsy 17.2 ± 6.1
Organ involvement at diagnosis
Cutaneous signs, n (%) 25 (18.8)
Ear, nose, throat, n (%) 46 (34.6)
Heart, n (%) 8 (6.0)
Digestive, n (%) 7 (5.3)
Lung, n (%) 48 (36.1)
Neurological, n (%) 19 (14.3)
Renal (at kidney biopsy)
Serum creatinine, µmol/L (ICQ) 279.0 (133–419)
eGFR, mL/min/1.73 m2 (ICQ) 20.7 (11–43)
Proteinuria, g/g (ICQ) 1.67 (0.8–2.9)
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Table 1. Cont.
All, n = 133
Proteinuria > 3g/g, n (%) 31 (23.3)
Need for renal replacement therapy, n (%) 30 (22.6)




Plasma exchange 38 (28.6)
Outcomes, n (%)
End-stage renal disease 35 (26.3)
Death 26 (19.5)
BMI, body mass index; ANCA, antineutrophil cytoplasmic antibbody; GPA, granulomatosis with polyangiitis; MPA,
micropolyangeitis; BVAS, Birmingham vasculitis activity score; ICQ, interquartile; eGFR, estimated glomerular
filtration rate.
3.2. Venous Thromboembolic Events
We first analyzed the frequency and sites of VTE. Eight patients (6%) had history of VTE before
ANCA-GN diagnosis. Twenty-five VTE occurred in 23 patients (17.3%) during the follow-up. The median
delay to first VTE was 3.03 months. VTE were predominantly DVT with leg localization, while pulmonary
embolism occurred in 7 patients (5.2%). In 4 cases, DVT developed as a complication of venous catheter
which was required for hemodialysis. The estimated one-year incidence of VTE was 12.4%. These data are
reported in Table 2. Figure 2 reports the survival free of VTE in the study population.
Table 2. Description of venous thromboembolic events.
Venous Thromboembolism (VTE)
Previous history of VTE, n (%) 8 (6.0)
Number of patients, n (%) 23 (17.3)
Number of episodes 25
Nature of VTE
DVT leg, n (%) 16 (64.0)
On femoral catheter, n (%) 4 (25.0)
PE, n (%) 7 (28.0)
With DVT, n (%) 1 (14.3)
Others *, n (%) 2 (8.0)
Diagnosis of first VTE, n (%)
Ultrasounds 14 (60.9)
CT scan 5 (21.7)
Chest scintigraphy 2 (8.70)
Other ** 1 (4.35)
Median delay to first episode, months (ICQ) 3.03 (0.8–15)
Occurrence on initial hospital stay, n (%) 4 (17.4)
Occurrence within the 3 months from AAV diagnosis 11 (47.8)
AAV, ANCA-associated vasculitis; DVT, deep vein thrombosis; PE, plasma exchange; VTE, venous thromboembolism.
* Central retinal vein thrombosis, n = 1; renal vein thrombosis, n = 1. ** Fundus examination.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 12 
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Anticardiolipid antibodies, anti-beta2 GP1 antibodies, and lupus anticoagulants were searched in
64 (48.1%), 55 (41.3%), and 41 (30.8%) patients, respectively. In those that had at least one test (n = 67),
abnormality of at least one test was detected in 8 patients (11.9%). These data are reported in Table S1.
3.3. Comparison of Patients According to VTE Occurrence
Patients that experienced at least one VTE had lower serum albumin concentration (p = 0.040)
and were less frequently on statin therapy at AAV diagnosis (p = 0.009). Age was not significantly
different (p = 0.081) between groups, and no significant difference was observed according to gender,
AAV phenotype, and ANCA subtype. At ANCA-GN diagnosis, AAV activity based on BVAS and
C-reactive protein level was comparable between groups and no difference in organ involvement was
observed. Remission induction treatment was also not significantly different and plasma exchange use
was comparable between groups. These data are reported in Table 3.
Table 3. Comparison of baseline characteristics of patients according to venous thromboembolic
events occurrence.
VTE p
Yes, n = 23 No, n = 110
Baseline characteristics
Gender (M/F) 11/12 72/38 0.244
Age (years) 69.7 ± 10.1 64.1 ± 14.6 0.081
BMI (kg/m2) 24.7 ± 3.3 24.5 ± 4.7 0.930
BMI > 30 kg/m2, n (%) 1 (4.3) 13 (11.8) 0.462
Heart disease, n (%) 3 (13.0) 12 (10.9) 0.724
Atrial fibrillation, n (%) 1 (4.3) 6 (5.4) 1.000
Past history of cancer, n (%) 4 (17.4) 15 (13.6) 0.743
Hypertension, n (%) 16 (69.6) 56 (50.9) 0.102
Diabetes mellitus, n (%) 5 (21.7) 13 (11.8) 0.206
History of VTE, n (%) 2 (8.7) 6 (20.9) 0.626
ANCA-associated vasculitis characteristics
Clinical diagnosis, n (%)
GPA/MPA, n (%) 8 (34.8)/15 (65.2) 37 (33.6)/73 (66.4) 0.916
Newly diagnosed, n (%) 22 (95.6) 100 (90.9) 0.689
ANCA type, n (%)
PR3-ANCA 3 (13.0) 36 (32.7) 0.078
MPO-ANCA 18 (78.3) 68 (61.8) 0.134
ANCA negative 2 (8.7) 6 (5.4) 0.626
BVAS at ANCA-GN onset 16.7 ± 4.4 17.3 ± 6.4 0.653
Organ involvement at diagnosis, n (%)
Cutaneous signs 4 (17.4) 21 (19.1) 1.000
Ear, nose, throat 8 (34.8) 38 (34.5) 0.983
Heart 1 (4.3) 7 (6.4) 1.000
Digestive 0 (0.0) 7 (6.4) 0.605
Lung 8 (34.8) 40 (36.4) 0.885
Neurological 2 (8.7) 17 (15.4) 0.525
Renal (at AAV diagnosis or relapse)
Serum creatinine, µmol/L, median (ICQ) 288.0 (172–525) 260.0 (122–408) 0.421
eGFR, mL/min/1.73 m2, median (ICQ) 14.8 (8–39) 22.7 (11–45) 0.285
Proteinuria/creatinunuria, g/g, median (ICQ) 1.27 (0.8–2.7) 1.74 (0.9–3.1) 0.807
Proteinuria > 3 g/g, n (%) 3 (13.0) 28 (25.4) 0.281
Need for renal replacement therapy, n (%) 7 (30.4) 23 (20.9) 0.410
Hospital stay
Length of stay at initial admission, days, median
(ICQ) 13.0 (6–24) 12.0 (5–21) 0.564
Admission in ICU at AAV diagnosis or relapse, n (%) 2 (8.7) 8 (7.3) 0.823
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Table 3. Cont.
VTE p
Yes, n = 23 No, n = 110
Biology at ANCA-GN onset
C-reactive protein, mg/L, median (ICQ) 56.5 (24–178) 56.9 (18–150) 0.847
Serum albumin, g/L 26.4 ± 4.8 29.8 ± 6.5 0.040
Treatment at ANCA-GN onset, n (%)
Antiplatelet agents 2 (8.7) 29 (26.4) 0.102
Anticoagulant therapy 1 (4.3) 16 (14.5) 0.304
Statin therapy 3 (13.0) 46 (41.8) 0.009
Induction remission regimen
Cyclophosphamide 20 (87.0) 96 (87.3) 1.000
Rituximab 3 (13.0) 4 (3.6) 0.099
Plasma exchange 8 (34.8) 30 (27.3) 0.468
3.4. Risk Factor of VTE Occurrence
In the univariate analysis, age, serum albumin concentration, statin therapy at ANCA-GN
diagnosis, and rituximab induction were significantly associated with the risk of developing VTE.
In the multivariate analysis, only lack of statin therapy at AAV diagnosis was significantly associated
with VTE occurrence (HR 4.73, p = 0.042), while the association with serum albumin was borderline
(HR 2.26, p = 0.057). Age and rituximab treatment were no longer associated with VTE after adjustment.
These results are presented in Table 4.
Table 4. Univariate and multivariate analysis of risk factors associated with occurrence of venous
thromboembolic events.
Univariate Analysis Multivariate Analysis
HR (CI) p HR (CI) p
Age * 1.55 (1.06–2.26) 0.022 1.38 (0.94–2.03) 0.101
Hypertension (yes) 2.22 (0.91–5.47) 0.082 - -
PR3-ANCA (yes) 0.40 (0.12–1.37) 0.144 - -
Serum albumin at onset ** 2.42 (1.09–5.39) 0.030 2.26 (0.98–5.23) 0.057
Antiplatelet agents (no) 3.61 (0.84–15.6) 0.085 - -
Statin therapy (no) 5.07 (1.49–17.2) 0.009 4.73 (1.06–21.1) 0.042
Rituximab (yes) 4.52 (1.29–15.8) 0.018 2.87 (0.61–13.6) 0.182
* Per 10 year increment. ** Per 10 g/L decrease.
Apart from being more frequently on antiplatelet agents, patients on statin therapy did not
significantly differ at ANCA-GN onset as compared to those without statins (Table S2). Moreover,
the rate of statin treatment was not significantly different between centers (Figure S1).
3.5. Prognosis of AAV Patients with VTE
In a last step, we analyzed the prognosis associated with VTE occurrence within the first 3
months (early VTE) following ANCA-GN diagnosis. We observed that patients with early VTE
(n = 12) developed more frequently ESRD (66.6% (n = 8) versus 22.3% (n = 27), p = 0.001). However,
no relationship between early VTE and death (VTE group 25.0% (n = 3) versus 19.0% (n = 23), p = 0.628)
or AAV relapse (VTE group 33.3% (n = 4) versus 29.7%, p = 1.000) was observed. Given that kidney
histological involvement is associated with renal outcome [14], we searched for an association between
renal histopathology and VTE occurrence. However, we did not observe any difference in histological
injury between patients with and without VTE within the first 3 months following ANCA-GN diagnosis,
as assessed using Berden classification (Figure 3).
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Figure 3. Kidney biopsy histology according to early venous thro boe bolism (VTE) occurrence.
(A) percentage of normal, cres ntic, or scl tic glomeruli in patients with and without early VTE.
(B) percentage of patients with VTE according to Berden’s classification. I, focal; II, crescentic; III,
mixed; and IV, sclerotic form.
4. Discussion
In the present study, we confirm a high incidenc of VTE in ANCA-GN patients. Indeed,
VTE occurred in 17.3% of patients at the end of follow-up, representing an estimated one-year incidence
of 12.4%. While the univariate analysis identified age, low serum albumin at ANCA-GN onset,
lack of statin therapy, and rituximab as significant risk factors of VTE; in the multivariate analysis,
only statin therapy was significantly associated with a lower risk of VTE. To the best of our knowledge,
this observation suggesting antithrombotic action of statins has not yet been reported in ANCA-GN
patients and may open new therapeutic perspectives.
The antithrombotic action of statin therapy has been observed in human prospective randomized
clinical trials [20,21]. A recent met -analysis comprisi g m re than three million partici ants from
cohort studies and randomized control trials showed a significant risk reduction of DVT with a RR
of 0.75 in patients on statin therapy as compared to patients on placebo [22]. Interestingly, in this
meta-analysis, a greater reduction risk of VTE was observed in the subgroup of patients with higher
VTE risk (RR 0.46). Poten ial protect ve actions of statins may be explained by several ways. Indeed,
several in vitro and in vivo animal and human studies have demonstrated an impact of statins on blood
coagulation [23,24]. In addition to their anti-inflammatory action, statins have been shown to favor an
anticoagulant state by reducing tissue factor expression, enhancing the protein C activity by increasing
thrombomodulin expression on endothelial cells [25], and by decreasing plasminogen activator inhibitor
1 and increasing tissue plasminogen activator [26]. In the present study, lack of statin therapy conferred
a 4.7-fold risk of developing VTE in our cohort. Thus, given that anti-thrombotic properties of statins
may be stronger in patients at high VTE risk, we suggest that their anti-thrombotic action may be greatly
enhanced in ANCA-GN patients, which could account for our results. Interestingly, patients under
statin therapy at AAV diagnosis were more frequently under antiplatelet agents as compared to
patients without statins. However, no difference was present as regards to hypertension or diabetes,
nor to cholesterol concentration at ANCA-GN diagnosis between patients with and without statins.
Moreover, the rate of statin therapy was not significantly different between centers suggesting the lack
of a center effect.
In the two major previous studies that analyzed VTE in AAV patients, the incidence of VTE
was 9.8% and 12%, thus lower than the incidence observed in the present study [2,4]. In the study
from Kronbichler et al., there was a trend towards a higher incidence of VTE in the MEPEX trial that
included patients with severe renal disease [5], which is in accordance with the higher incidence
of VTE in our study. The differences in VTE incidences may also be explained by heterogeneity in
disease presentation, severity, and stages of disease (flare versus remission) of patients included in
past studies [2,4].
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We observed that most VTE occurred soon after AAV diagnosis when patients had active vasculitis.
The median delay to VTE was about 3 months after ANCA-GN diagnosis, which corresponds to the
remission-induction therapeutic phase. Given that no systematic VTE screening was performed in
our study, it is probable that the true delay between AAV diagnosis and VTE occurrence may be
shorter. Thus, most VTE occurred in a period when several risk factors of VTE are present, such as
hospitalization, immobilization related to disease severity, and the need for central venous access for
hemodialysis or plasmapheresis.
We were not able to study the role for endogenous hypercoagulable factors in our study. Only one
third of patients were screened for APL and/or LA, not allowing to investigate relationship with VTE.
We observed a low prevalence of APL and lupus anticoagulant in screened patients.
Interestingly, we observed that patients that experienced VTE within the first 3 months following
AAV diagnosis developed more frequently ESRD. The kidney involvement of these patients as assessed
by kidney biopsy was not significantly different as compared to other patients. We also did not observe
any significant difference in treatment regimens that could explain this observation. Unfortunately,
the low number of patients with this condition does not allow us to analyze causative factors extensively.
Interestingly, serum albumin appeared as a potential risk factor for VTE in ANCA-GN patients in
our study. Indeed, we observed an association between serum albumin at baseline with an HR of 2.42 for
each 10 g/L albumin decrease in the univariate analysis. The relationship between hypoalbuminemia
and VTE is well documented in patients with nephrotic syndrome, where hypoalbuminemia is mainly
the consequence high albuminuria [27,28], and has also been evidenced as an independent risk factor of
VTE in a recent study conducted in AAV patients with and without renal involvement [13]. In our study,
proteinuria was not different between patients with and without VTE, suggesting that mechanisms
other than proteinuria may be involved to explain more profound hypoalbuminemia in VTE patients.
Finally, serum albumin was no longer associated with VTE in the multivariate analysis, maybe because
our study was underpowered. Further studies should focus on this aspect to better understand the
factor favoring venous thrombosis in ANCA-GN patients.
In contrast to previous studies [5], we did not observe any association between VTE and AAV
organ involvement, C-reactive protein level or BVAS at presentation. This may be explained by our
design that only included patients with ANCA-GN with finally poor representation of patients with
other organ involvement. The lack of association with inflammation may also be related to the fact that
patients of our study had high disease activity at presentation mainly driven by their renal involvement
(median BVAS 17.2), limiting any comparison between patients with severe and milder disease activity.
In a recent post-hoc analysis of the RAVE trial [12], Kronbichler et al. showed that heart involvement,
pulmonary hemorrhage, PR3-ANCA, and microscopic hematuria were independently associated with
VTE development. However, it is important to underline that patients with serum creatinine above
354 µmol/L were excluded from RAVE study [12] and that kidney involvement of RAVE study patients
was mild with a mean eGFR above 50 at baseline as compared to 20 mL/min/1.73 m2 in our study.
Finally, we were not able to identify “classical” risk factors found in previous studies, but found
association with novel factors not yet or poorly reported. This may be related to the fact that patients
in our cohort had a very detailed phenotype allowing us to analyze a large number of potential risk
factors. Another explanation may be that that classical risk factors of VTE could be overcome in the
context of ANCA-GN.
Our study has several limitations starting with its observational design. We did not perform
systematic radiological screening of DVT, thus some VTE may have been missed. Moreover, we did not
perform systematic screening of blood clotting and of APL antibodies and the use of thromboprophylaxis
at ANCA-GN diagnosis was not collected. However, despite these limitations, this study is the first to
analyze specifically the incidence and risk factors of VTE in a well characterized population of patients
with ANCA-GN.
In conclusion, in line with previous studies, we show a high incidence of VTE in ANCA-GN
patients, predominantly within the first months following ANCA-GN diagnosis. The present study
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identifies statin therapy as an independent risk factors of VTE in ANCA-GN patients, thus suggesting
a protective role of statins and opening interesting research and therapeutic perspectives. Furthermore,
these results give some suggestions for future research that should focus on the effect of albumin levels
on VTE risk and on the impact of experiencing VTE on renal outcome. Thus, these results may help
identifying ANCA-GN patients with higher VTE risk and defining specific preventive strategies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/10/3177/s1,
Figure S1: Statin treatment frequency according to center, Table S1: Search for a hypercoagulability state. Results are
given as absolute values and percentages, Table S2: Baseline characteristics of patients according to statin treatment
at diagnosis.
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